$EVOK
Evoke Pharma Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021056208 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $930.5K $0.00 $0.00
YoY Change
Cost Of Revenue $58.44K
YoY Change
Gross Profit $872.0K
YoY Change
Gross Profit Margin 93.72%
Selling, General & Admin $2.635M $1.875M $1.180M
YoY Change 40.57% 131.43% 28.26%
% of Gross Profit 302.19%
Research & Development $81.70K $210.0K $5.782M
YoY Change -61.1% -74.47% 379.6%
% of Gross Profit 9.37%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.775M $2.080M $6.965M
YoY Change 33.45% 27.06% 227.96%
Operating Profit -$1.845M -$2.080M -$6.965M
YoY Change -11.29% 27.06% 227.96%
Interest Expense $126.0K $50.53K $2.914K
YoY Change 149.42% 487.74% -69.78%
% of Operating Profit
Other Income/Expense, Net -$124.6K -$49.50K -$2.429K
YoY Change 151.75% -675.72% -125.19%
Pretax Income -$1.969M -$2.130M -$6.970M
YoY Change -7.54% 30.67% 230.33%
Income Tax
% Of Pretax Income
Net Earnings -$1.969M -$2.129M -$6.967M
YoY Change -7.5% 30.78% 229.57%
Net Earnings / Revenue -211.67%
Basic Earnings Per Share -$0.73
Diluted Earnings Per Share -$726.3K -$81.45K -$278.9K
COMMON SHARES
Basic Shares Outstanding 2.712M
Diluted Shares Outstanding 2.712M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.14M $6.280M $7.990M
YoY Change 77.42% -3.38% 7.39%
Cash & Equivalents $11.10M $6.281M $7.990M
Short-Term Investments
Other Short-Term Assets $11.55K $11.55K $200.0K
YoY Change 0.0% 0.0% 1631.45%
Inventory $225.2K $86.15K
Prepaid Expenses
Receivables $222.2K
Other Receivables $0.00
Total Short-Term Assets $11.60M $6.710M $8.200M
YoY Change 72.89% -7.98% 8.45%
LONG-TERM ASSETS
Property, Plant & Equipment $49.12K $40.00K $70.00K
YoY Change 22.8% 0.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $49.12K $40.00K $70.00K
YoY Change 22.8% 13.0% 0.29%
TOTAL ASSETS
Total Short-Term Assets $11.60M $6.710M $8.200M
Total Long-Term Assets $49.12K $40.00K $70.00K
Total Assets $11.65M $6.750M $8.270M
YoY Change 72.59% -7.88% 8.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $530.5K $770.0K $600.0K
YoY Change -31.1% -33.04% 46.34%
Accrued Expenses $859.9K $750.0K $930.0K
YoY Change 14.65% -25.0% 5.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $100.0K $100.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.390M $6.620M $6.640M
YoY Change -79.0% 207.31% 416.72%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $2.000M $2.000M
YoY Change 150.0%
Other Long-Term Liabilities $486.3K $50.00K
YoY Change 872.54%
Total Long-Term Liabilities $5.486M $2.053M $2.000M
YoY Change 167.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.390M $6.620M $6.640M
Total Long-Term Liabilities $5.486M $2.053M $2.000M
Total Liabilities $6.877M $8.674M $8.641M
YoY Change -20.72% 303.46% 569.82%
SHAREHOLDERS EQUITY
Retained Earnings -$105.8M -$96.62M -$94.49M
YoY Change 9.45% 14.59%
Common Stock $110.5M $94.69M $94.11M
YoY Change 16.72% 5.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.773M -$1.923M -$373.7K
YoY Change
Total Liabilities & Shareholders Equity $11.65M $6.751M $8.267M
YoY Change 72.57% -7.87% 8.35%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$1.969M -$2.129M -$6.967M
YoY Change -7.5% 30.78% 229.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.892M -$1.810M -$1.560M
YoY Change 225.53% 72.38% -4.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 313.1K 110.0K 5.410M
YoY Change 184.65% -8.33% 7.34%
NET CHANGE
Cash From Operating Activities -5.892M -1.810M -1.560M
Cash From Investing Activities
Cash From Financing Activities 313.1K 110.0K 5.410M
Net Change In Cash -5.579M -1.700M 3.850M
YoY Change 228.18% 82.8% 12.9%
FREE CASH FLOW
Cash From Operating Activities -$5.892M -$1.810M -$1.560M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2021Q3 us-gaap Inventory Net
InventoryNet
225217
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49117
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
49117
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2129105
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6450979
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4387284
us-gaap Operating Expenses
OperatingExpenses
10838263
us-gaap Operating Income Loss
OperatingIncomeLoss
-10838263
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4896
us-gaap Interest Expense
InterestExpense
53442
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48546
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25191359
us-gaap Net Income Loss
NetIncomeLoss
-6865590
CY2020Q4 evok Milestone Payable
MilestonePayable
5000000
CY2020Q4 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
104168
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-261298
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1390435
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7535677
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
486268
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
112994
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5486268
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5112994
CY2021Q3 us-gaap Liabilities
Liabilities
6876703
CY2020Q4 us-gaap Liabilities
Liabilities
12648671
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3266
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2662
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110520641
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
95667776
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105750651
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98885061
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4773256
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3214623
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11649959
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9434048
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81699
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1874578
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7115605
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2775295
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2079610
us-gaap Operating Expenses
OperatingExpenses
7861797
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1844846
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2079610
us-gaap Operating Income Loss
OperatingIncomeLoss
-6604292
evok Forgiveness Of Paycheck Protection Loan And Accrued Interest
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest
105130
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1421
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1033
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7596
CY2021Q3 us-gaap Interest Expense
InterestExpense
126027
CY2020Q3 us-gaap Interest Expense
InterestExpense
50528
us-gaap Interest Expense
InterestExpense
374024
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-124606
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-49495
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1969452
evok Accrued Compensation
AccruedCompensation
205442
evok Accrued Compensation
AccruedCompensation
127740
evok Accrued Interest Expense
AccruedInterestExpense
374236
evok Accrued Interest Expense
AccruedInterestExpense
53442
evok Milestone Payment
MilestonePayment
-5000000
evok Milestone Payment
MilestonePayment
5000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10355746
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
75000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26146220
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32028850
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3214623
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
561348
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1304846
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13070154
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2605495
CY2021Q2 evok Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
45454
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6421
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1969452
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4773256
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
310162
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21250
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1790309
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2921648
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362955
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
68038
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3309116
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6967395
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-373676
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
478574
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
98165
CY2020Q3 evok Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
2627
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2129105
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1923415
us-gaap Net Income Loss
NetIncomeLoss
-6865590
us-gaap Net Income Loss
NetIncomeLoss
-10886809
evok Forgiveness Of Paycheck Protection Loan And Accrued Interest1
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1
-105130
us-gaap Share Based Compensation
ShareBasedCompensation
1424754
us-gaap Share Based Compensation
ShareBasedCompensation
1151691
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
198855
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-1055913
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-261552
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-835632
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-370639
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4918503
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13070154
evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
313107
evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
3309116
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45454
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2627
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
119415
evok Bad Debt Expense
BadDebtExpense
0
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
104168
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13428715
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5535326
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3072969
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
616823
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8068939
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5663833
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11141908
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6280656
us-gaap Loans Assumed1
LoansAssumed1
105130
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
86000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6830006
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6119660
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6830006
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6119660
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000.0
CY2020Q3 evok Common Stock Weighted Average Price Per Share
CommonStockWeightedAveragePricePerShare
2.42
CY2021Q3 evok Common Stock Weighted Average Price Per Share
CommonStockWeightedAveragePricePerShare
1.47
CY2021Q3 evok Common Stock Weighted Average Price Per Share
CommonStockWeightedAveragePricePerShare
1.47
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
463995
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
478574
us-gaap Share Based Compensation
ShareBasedCompensation
1424754
us-gaap Share Based Compensation
ShareBasedCompensation
1151691

Files In Submission

Name View Source Status
0001564590-21-056208-index-headers.html Edgar Link pending
0001564590-21-056208-index.html Edgar Link pending
0001564590-21-056208.txt Edgar Link pending
0001564590-21-056208-xbrl.zip Edgar Link pending
evok-10q_20210930.htm Edgar Link pending
evok-10q_20210930_htm.xml Edgar Link completed
evok-20210930.xsd Edgar Link pending
evok-20210930_cal.xml Edgar Link unprocessable
evok-20210930_def.xml Edgar Link unprocessable
evok-20210930_lab.xml Edgar Link unprocessable
evok-20210930_pre.xml Edgar Link unprocessable
evok-ex311_6.htm Edgar Link pending
evok-ex312_8.htm Edgar Link pending
evok-ex321_7.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g3qlaocadqly000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending